Objectif The prevalence and occurrence of inflammatory bowel diseases have experienced steep increase in Western countries, as well as in populations considered ‘low risks’ before. Nevertheless, currently available therapies, including anti-tumor necrosis factor-α (TNF-α) therapy, have numerous limitations and are often associated with severe adverse effects. Therefore, the research project aims at safer and effective inflammatory bowel disease therapy by proposing development of a novel multifunctional polymeric film based platforms for oral delivery of anti-TNF-α. The drug delivery system comprises of a nanoformulation encapsulating anti-TNF-α which are then entrapped into a mucoadhesive polymeric film. These mucoadhesive polymeric films are composed of second generation highly efficient mucoadhesive S-protected thiolated polymer, which are then loaded inside pH responsive capsules for site-specific delivery. The proposed system would provide enhanced therapeutic outcome by minimizing side effect via reduction of the frequency of dosing and targeted delivery of anti-TNF-α at the site of action, which would be achieved by preventing the degradation of the encapsulated biologics, prolonging the gastrointestinal retention time of the drug delivery system, increasing drug accumulation at target site and minimizing the systemic absorption. Furthermore, additional unique benefits of the proposed systems such as the biocompatibility, biodegradability, sustained drug release at targeted site, mucus penetration of the nanoformulation, and use of accessible and patient friendly oral route, can widen its biomedical applicability and explore its use in clinics and pharmaceutical industries. Champ scientifique medical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasenatural scienceschemical sciencespolymer sciencesmedical and health sciencesbasic medicineimmunologyautoimmune diseasesengineering and technologynanotechnologynano-materialsnatural sciencesbiological scienceshistology Mots‑clés oral antibody delivery biomaterials nanosystems anti-TNF-alpha inflammatory bowel disease Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Thème(s) MSCA-IF-2016 - Individual Fellowships Appel à propositions H2020-MSCA-IF-2016 Voir d’autres projets de cet appel Régime de financement MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinateur UNIVERSITE CATHOLIQUE DE LOUVAIN Contribution nette de l'UE € 172 800,00 Adresse PLACE DE L UNIVERSITE 1 1348 Louvain La Neuve Belgique Voir sur la carte Région Région wallonne Prov. Brabant Wallon Arr. Nivelles Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 172 800,00
